MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells

  • Authors:
    • Fenfen Xiang
    • Rong Wu
    • Zhenhua  Ni
    • Chunying  Pan
    • Yueping Zhan
    • Jian  Xu
    • Xianpeng  Meng
    • Xiangdong Kang
  • View Affiliations

  • Published online on: August 21, 2014     https://doi.org/10.3892/or.2014.3433
  • Pages: 1837-1844
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of the present study was to investigate the relationship between myeloid differentiation primary response gene 88 (MyD88) expression and the resistance to paclitaxel of A549 lung cancer cells. In order to achieve MyD88 gene overexpression or knockdown in the A549 cell line, the cells were infected with lentivirus carrying MyD88 gene or shRNA to MyD88. MyD88 mRNA and protein expression was measured by RT-qPCR, immunohistochemistry and western blotting after infection for confirmation. Cell prolife­ration was detected by the WST-1 assay. Flow cytometry was used to measure the cell cycle and apoptosis. The transwell migration assay was used to observe the change of migration of transfected cells. The results showed that the overexpression of MyD88 increased the resistance of lung cancer A549 cells to paclitaxel, while the suppression of MyD88 increased the sensitivity of A549 lung cancer cells to paclitaxel. Following the paclitaxel treatment, a decreased apoptosis and G2 phase ratio, an increased cell migration ratio, and an increased production of IL-8 were found in MyD88‑overexpressed A549 cells. The western blot analysis revealed that Myd88 overexpression resulted in an increased level of Bcl-2 but a decreased level of Bax in A549 cells. These findings suggested that the expression level of MyD88 is closely associated with paclitaxel resistance in A549 lung cancer cells. Thus, the downregulation of MyD88 in A549 cells increased its sensitivity to paclitaxel treatment, whereas the upregulation of MyD88 substantiates its paclitaxel resistance.
View Figures
View References

Related Articles

Journal Cover

November-2014
Volume 32 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xiang F, Wu R, Ni Z, Pan C, Zhan Y, Xu J, Meng X and Kang X: MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells. Oncol Rep 32: 1837-1844, 2014.
APA
Xiang, F., Wu, R., Ni, Z., Pan, C., Zhan, Y., Xu, J. ... Kang, X. (2014). MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells. Oncology Reports, 32, 1837-1844. https://doi.org/10.3892/or.2014.3433
MLA
Xiang, F., Wu, R., Ni, Z., Pan, C., Zhan, Y., Xu, J., Meng, X., Kang, X."MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells". Oncology Reports 32.5 (2014): 1837-1844.
Chicago
Xiang, F., Wu, R., Ni, Z., Pan, C., Zhan, Y., Xu, J., Meng, X., Kang, X."MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells". Oncology Reports 32, no. 5 (2014): 1837-1844. https://doi.org/10.3892/or.2014.3433